Business Context and Reporting Period
This Form 8-K is filed by Elevai Labs Inc. (not PMGC Holdings Inc. as indicated in metadata) for the reporting period ending July 31, 2024. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Newport Beach, CA. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company sold notes with an aggregate principal amount of $1,150,000 in a private placement.
- Original Issue Discount (OID): The notes were issued with an OID of $150,000.
- Equity Issuance: As consideration, the Company issued 1,299,999 shares of common stock to purchasers on August 2, 2024.
- Interest Rate: The notes do not bear interest unless an event of default occurs, at which point the rate is 14%.
- Maturity: The notes mature 90 days from July 31, 2024.
- Liquidity and Cash Flow: The filing text does not provide specific values for current cash flow, liquidity ratios, or overall revenue/profit metrics.
Material Changes and Covenants
The primary material change is the incurrence of new short-term debt and the dilution of existing shareholders via the issuance of nearly 1.3 million shares. Key covenants and terms include:
- Dividend Restriction: While notes are outstanding, the Company cannot declare or pay cash dividends or distributions on equity interests.
- Debt Restriction: The Company is restricted from incurring or guaranteeing certain types of indebtedness.
- Registration Rights: The Company must file a registration statement within 15 days of the closing date to allow purchasers to resell the shares, with a requirement to make it effective within 60 days.
- Participation Rights: Purchasers have the right to participate in up to 20% of any subsequent financing for cash consideration (excluding Regulation A+ offerings) for 12 months post-closing.
- Guarantees: The Company's wholly owned subsidiaries (Elevai Skincare Inc., Elevai Research Inc., and Elevai Biosciences Inc.) have guaranteed the payment of obligations under the notes.
Outlook, Risks, and Contingencies
The filing does not provide forward-looking guidance, revenue outlook, or management commentary regarding future performance. However, the following risks and contingencies are noted:
- Default Risk: In the event of default, purchasers may require the Company to redeem all or any portion of the notes, and interest accrues at 14%.
- Regulatory Compliance: The transaction relies on exemptions under Section 4(a)(2) of the Securities Act and/or Regulation D.
- Operational Constraints: The covenants limit the Company's ability to raise additional capital on different terms or pay dividends during the note term.
Investor Verification Checklist
- Verify the exact closing date of the private placement (August 2, 2024) and the effective date of the subsequent registration statement.
- Confirm the current cash position of Elevai Labs Inc. to assess the ability to repay the $1,150,000 principal within 90 days.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Note (Exhibit 10.2) for specific definitions of "event of default."
- Monitor the Company's compliance with the 15-day and 60-day filing deadlines for the resale registration statement.
- Assess the impact of the 1,299,999 new shares on existing shareholder dilution.